Vical

News

Vical slashes staff after culling phase II antifungal

US biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, its last remaining clinical-stage asset.

News

Pfizer, Valneva Lyme vaccine starts review in Europe

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks